External validation of anti-Müllerian hormone based prediction of live birth in assisted conception

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Khader, Amani ^a   Lloyd, Suzanne M ^a   McConnachie, Alex ^a   Fleming, Richard ^b   Grisendi, Valentina ^c   La Marca, Antonio ^c   Nelson, Scott M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Glasgow Centre for Reproductive Medicine   (United Kingdom)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

AMH; IVF; Live birth prediction

Indexed keywords

MUELLERIAN INHIBITING FACTOR;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; CONTROLLED STUDY; EMBRYO TRANSFER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONE DETERMINATION; HUMAN; INFERTILITY THERAPY; LIVE BIRTH; MAJOR CLINICAL STUDY; NOMOGRAM; OBSERVED PROBABILITY; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTED PROBABILITY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; UNITED KINGDOM; VALIDATION PROCESS;

EID: 84871870326     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-3     Document Type: Article

References (19)

1. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. SK Sunkara, V Rittenberg, N Raine-Fenning, S Bhattacharya, J Zamora, A Coomarasamy, Hum Reprod 2011 26 1768 1774 10.1093/humrep/der106 21558332
2. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). A La Marca, G Sighinolfi, D Radi, C Argento, E Baraldi, AC Artenisio, G Stabile, A Volpe, Hum Reprod Update 2010 16 113 130 10.1093/humupd/dmp036 19793843
3. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles implications for individualization of therapy. SM Nelson, RW Yates, R Fleming, Hum Reprod 2007 22 2414 2421 10.1093/humrep/dem204 17636277 (Pubitemid 47289055)
4. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. TH Lee, CH Liu, CC Huang, KC Hsieh, PM Lin, MS Lee, Reprod Biol Endocrinol 2009 7 100 10.1186/1477-7827-7-100 19761617
5. Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine insemination. HW Li, WS Biu Yeung, EY Lan Lau, PC Ho, EH Ng, Fertil Steril 2010 94 2177 2181 10.1016/j.fertnstert.2009.12.059 20171627
6. The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos. K Majumder, TA Gelbaya, I Laing, LG Nardo, Eur J Obstet Gynecol Reprod Biol 2010 150 166 170 10.1016/j.ejogrb.2010.02.029 20223579
7. Anti-Mullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. N Gleicher, A Weghofer, DH Barad, Fertil Steril 2010 94 2824 2827 10.1016/j.fertnstert.2010.04.067 20538269
8. Anti-Mullerian Hormone (AMH) based prediction model for the live birth in assisted reproductive technology (ART). A La Marca, SM Nelson, G Sighinolfi, M Manno, E Baraldi, L Roli, S Xella, T Marsella, D Tagliasacchi, R D'Amico, A Volpe, RBM online 2011 22 341 349 21317041
9. Risk prediction models: II. External validation, model updating, and impact assessment. KGM Moons, AP Kengne, DE Grobbee, P Royston, Y Vergouwe, DG Altman, M Woodward, Heart 2012 98 691 698 10.1136/heartjnl-2011-301247 22397946
10. What do we mean by validating a prognostic model? DG Altman, P Royston, Stat Med 2000 19 453 473 10.1002/(SICI)1097-0258(20000229)19:4<453::AID- SIM350>3.0.CO;2-5 10694730 (Pubitemid 30126878)
11. Prediction models in reproductive medicine: a critical appraisal. E Leushuis, JW van der Steeg, P Steures, PMM Bossuyt, MJC Eijkemans, F van der Veen, BWJ Mol, PGA Hompes, Hum Reprod Update 2009 15 537 552 10.1093/humupd/dmp013 19435779
12. Evaluating prediction models in reproductive medicine. SFPJ Coppus, F van der Veen, BC Opmeer, BWJ Mol, PMM Bossuyt, Hum Reprod 2009 24 1774 1778 10.1093/humrep/dep109 19395365
13. Predicting live birth, preterm delivery, and low birth weight in infants born from in vitro fertilisation: a prospective study of 144,018 treatment cycles. SM Nelson, DA Lawlor, PLoS Med 2011 8 1000386 10.1371/journal.pmed. 1000386 21245905
14. Anti-Müllerian hormone: clairvoyance or crystal clear? SM Nelson, RA Anderson, FJ Broekmans, N Raine-Fenning, R Fleming, A La Marca, Hum Reprod 2012 27 631 636 10.1093/humrep/der446 22238112
15. Low concentration of circulating antimullerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. CP Hagen, S Vestergaard, A Juul, NE Skakkebaek, AM Andersson, KM Main, NH Hjollund, E Ernst, JP Bonde, RA Anderson, TK Jensen, Fertil Steril 2012 98 1602 1608 10.1016/j.fertnstert.2012.08.008 22959460
16. Pronostic en fécondation in vitro des patientes ayant une AMH basse et une FSH normale. V Grzegorczyk-Martin, M Khrouf, S Bringer-Deutsch, JM Mayenga, O Kulski, P Cohen-Bacrie, JL Benaim, J Belaisch-Allart, Gynecol Obstet Fertil 2012 40 411 418 10.1016/j.gyobfe.2012.02.001 22521986
17. Low AMH and GnRH-antagonist strategies. SM Nelson, R Fleming, Fertil Steril 2009 92 40 author reply e41 10.1016/j.fertnstert.2009.05.056 19580967
18. Live birth chances in women with extremely low-serum anti-Mullerian hormone levels. A Weghofer, W Dietrich, DH Barad, N Gleicher, Hum Reprod 2011 26 1905 1909 10.1093/humrep/der134 21531994
19. Effect of age on decisions about the numbers of embryos to transfer in assisted conception: a prospective study. DA Lawlor, SM Nelson, Lancet 2012 379 521 527 10.1016/S0140-6736(11)61267-1 22243709